Clinical Trial Update: Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating long-acting nasal insulin detemir for cognitive decline in Alzheimer’s disease and mild cognitive impairment has completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• nasal insulin detemir (long-acting insulin detemir) (insulin detemir)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Alzheimer's Disease, Mild Cognitive Impairment | Phase 2 | Status: COMPLETED | Results posted: 2018-02-01